Please join Carterra and WuXi Biologics at our upcoming symposium in Oxford, United Kingdom. You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:
Network with your peers. Lunch will be provided. Registration is required as seating is limited.
Companies presenting in 2024:
Agenda |
|
9:45 – 10:00 |
Arrive and Check-in |
10:00 – 10:30 |
Networking and Coffee/Tea |
10:30 – 10:45 |
Symposium Begins—Welcome |
10:45 – 11:15 |
Kirsty McHugh, PhD, Senior Postdoctoral Scientist, University of Oxford
|
|
Abstract: Plasmodium falciparum malaria is a major cause of morbidity and mortality, and new interventions are urgently needed. The P. falciparum reticulocyte-binding protein homolog 5 (PfRH5) antigen is a leading blood-stage vaccine candidate. Vaccines targeting PfRH5 have demonstrated antibody-mediated efficacy in clinical trials, but high, durable titers of inhibitory antibodies must be induced, a challenge which is difficult to meet with current generation vaccines. Our group have generated a broad panel of over 200 anti-PfRH5 monoclonal antibodies from PfRH5-vaccinated UK adult volunteers. By combining high throughput epitope binning using the Carterra LSA® platform with in vitro parasite growth inhibition assays we have revealed the diverse antigenic landscape of PfRH5 and identified inhibitory epitopes to a fine resolution. These results will help inform our next-generation vaccine design. |
11:15 – 11:45 |
Jon Popplewell, PhD, Field Application Scientist , Carterra |
|
Abstract: Carterra’s LSA® and LSAXT platforms have changed the landscape of drug discovery. Across small and large molecule therapies as well as vaccines, the power of high throughput multiplexing and innovative assay configurations is enabling new strategies to tackle the undruggable space and discover novel medicines. This talk will emphasize areas where HT-SPR technology continues to push the boundaries of real-time, label-free binding. With HT-SPR, research workflows benefit from seamless data integrations and the necessary breadth and depth of data to deliver on the promises of AI/ML-based drug discovery. |
11:45 – 13:00 |
Lunch and Networking |
13:00 – 13:30 |
Xavier Pierrat, PhD, Senior Investigator, Ichnos Sciences |
|
Abstract: The complexity in designing potent multispecific immune engagers to treat cancer is multi-factorial and relies on advanced screening capabilities to select the optimal molecules. The Ichnos discovery engine includes common light chain (cLC) Fab discovery by phage and mammalian display, and screening for optimal affinity, epitope, developability and architecture. To streamline this process, we have recently implemented the LSA® instrument enabling high affinity measurement, epitope binning and early developability assessment. |
13:30 – 14:00 |
Jiansheng Wu, PhD, VP, Head of Protein Sciences, WuXi Biologics |
|
Abstract: With increasing interest in bispecific antibodies (bsAbs) for therapeutic development and AI integration in drug discovery, the demand for high throughput (HTP) bsAb production has soared. However, bsAb production faces challenges such as heterogeneity, production complexity, and stability issues, which impact the quality of the final product. This presentation will reveal innovative strategies to address these challenges, from small-scale HTP production of a vast number of bispecific antibody pairings to efficient scale-up after identifying optimal pairings. Real-world case studies will demonstrate the successful application of these strategies, achieving high yield and purity (>99% heterodimers) of bsAbs. |
14:00 – 14:30 |
Ciarra McGoran, MSc, Associate Scientist, GSK |
|
Abstract: The Carterra LSA has provided us with the scope to generate affinities for hundreds of antibodies against several targets. However, when focusing on increasing throughput it is important to ensure that data quality is maintained. Since the introduction of the LSA to our labs, we have been developing new ways to obtain, analyse and store data. I will be discussing the optimisation of immobilisation methods to generate capture surfaces. In addition, I will discuss the impact this has had on our ability to characterise high affinity interactions, and on our confidence in our high throughput screening data. |
14:30 – 15:00 |
Networking and Refreshments |
15:00 |
Symposium Ends |